# US 2016/0258018 A1 · Marker for prenatal diagnosis and monitoring

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258018 A1
- Document ID: US20160258018A1
- Status: Published application
- Kind: A1
- Application number: 15/012,611
- Filed: 2016-02-01
- Published: 2016-09-08
- Earliest claimed: 2005-06-03
- Assignees: The Chinese University of Hong Kong
- Applicants: The Chinese University of Hong Kong
- Inventors: Yuk Ming Dennis Lo; Wai Kwun Rossa Chiu; Stephen Siu-Chung Chim; Yu-Kwan Tong; Chunming Ding
- Web page: https://patentgrep.com/patent/US20160258018A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.

## Claims

### Claim 1

A method for detecting or monitoring a pregnancy-associated disorder in a woman pregnant with a fetus, comprising the steps of:
(a) obtaining a blood sample from the woman;
(b) determining the methylation status of at least a portion of the maspin gene in the blood sample, wherein the portion of the maspin gene from the fetus and the portion from the woman are differentially methylated, thereby distinguishing the maspin gene from the woman and the maspin gene from the fetus in the blood sample;
(c) determining the level of the fetal maspin gene; and
(d) comparing the level of the fetal maspin gene with a standard control, wherein an increase or decrease from the standard control indicates the presence or progression of a pregnancy-associated disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the blood sample is whole blood.

### Claim 3 (depends on 1)

The method of claim 1, wherein the blood sample is plasma or serum.

### Claim 4 (depends on 1)

The method of claim 1, wherein the portion of the maspin gene from the woman is methylated and the portion from the maspin gene from the fetus is less methylated.

### Claim 5 (depends on 4)

The method of claim 4, wherein step (b) is performed by treating DNA present in the blood sample with a reagent that differentially modifies methylated and non-methylated DNA.

### Claim at position 6

-8. (canceled)

### Claim 9

A method for detecting or monitoring a pregnancy-associated disorder in a woman pregnant with a fetus, comprising the steps of:
(a) obtaining DNA in a blood sample from the woman;
(b) treating the DNA from step (a) with bisulfate; and
(c) performing an amplification reaction using the DNA from step (b) and two primers to amplify at least a portion of the maspin gene, wherein the portion of the maspin gene from the fetal DNA and the portion of the maspin gene from the maternal DNA in the blood sample are differentially methylated, and wherein at least one of the two primers binds differentially to the portion of the maspin gene from the fetus; and
(d) comparing the level of the amplified portion of the maspin gene from step (c) with a standard control, wherein an increase or decrease from the standard control indicates the presence or progression of a pregnancy-associated disorder.

### Claim 10 (depends on 9)

The method of claim 9, wherein the blood sample is whole blood.

### Claim 11 (depends on 9)

The method of claim 9, wherein the blood sample is plasma or serum.

### Claim 12 (depends on 9)

The method of claim 9, wherein the amplification reaction is a polymerase chain reaction (PCR).

### Claim at position 11

13-24. (canceled)

### Claim 25

A method for detecting the maspin gene from a fetus in the blood of a pregnant woman, comprising the steps of:
(a) obtaining a blood sample from the woman; and
(b) detecting at least a portion of the maspin gene, wherein the portion of the maspin gene is differentially methylated from the portion of the maspin gene from the maternal DNA in the blood sample, thereby detecting the maspin gene from the fetus.

### Claim 26 (depends on 25)

The method of claim 25, wherein the blood sample is whole blood.

### Claim 27 (depends on 25)

The method of claim 25, wherein the blood sample is plasma or serum.

### Claim 28

A method for detecting and monitoring a pregnancy-associated disorder, comprising the steps of:
(a) obtaining DNA in a blood sample from the woman;
(b) treating the DNA from step (a) with a reagent that differentially modifies methylated and non-methylated DNA;
(c) determining the nucleotide sequence of at least a portion of the maspin gene from step (b); and
(d) comparing the profile of the nucleotide sequences from step (c) with a standard control, wherein a change in the profile from the standard control indicates the presence or progression of a pregnancy-associated disorder.

### Claim 29 (depends on 28)

The method of claim 28, wherein the reagent comprises bisulfite.

### Claim 30 (depends on 28)

The method of claim 28, wherein the reagent comprises one or more enzymes that preferentially cleave methylated DNA.

### Claim 31 (depends on 28)

The method of claim 28, wherein the reagent comprises one or more enzymes that preferentially cleave unmethylated DNA.

### Claim at position 19

-40. (canceled)

### Claim 41

A method for detecting trisomy 18 in a fetus in a pregnant woman, comprising the steps of:
(a) obtaining DNA in a blood sample from the woman;
(b) treating the DNA from step (a) with a reagent that differentially modifies methylated and non-methylated DNA; and
(c) determining the levels of different alleles of the maspin gene from the fetal DNA, thereby determining the ratio of the alleles, wherein the different alleles have different methylation profile in at least portion of the maspin gene, and wherein an increase or a decrease in the ratio from a standard control indicates the presence of trisomy 18 in the fetus.

### Claim 42 (depends on 41)

The method of claim 41, wherein the reagent comprises bisulfite.

### Claim 43 (depends on 41)

The method of claim 41, wherein the reagent comprises one or more enzymes that preferentially cleave methylated DNA.

### Claim at position 23

-53. (canceled)

### Claim 54

A method for detecting trisomy 18 in a fetus in a pregnant woman, comprising:
(a) obtaining a blood sample from the woman;
(b) determining the methylation status of at least a portion of the maspin gene in the blood sample, wherein the portion of the maspin gene from the fetus and the portion from the woman are differentially methylated, thereby distinguishing the maspin gene from the woman and the maspin gene from the fetus in the blood sample; and
(c) determining the levels of two different alleles of the fetal maspin gene, wherein a deviation of the ratio of the levels of the two alleles from 1:1 indicates trisomy 18 in the fetus.

### Claim at position 25

-56. (canceled)
